Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

6,159.00GBp
22 Feb 2019
Change (% chg)

63.00 (+1.03%)
Prev Close
6,096.00
Open
6,100.00
Day's High
6,197.00
Day's Low
6,081.00
Volume
1,724,090
Avg. Vol
2,092,005
52-wk High
6,432.48
52-wk Low
4,710.50

Latest Key Developments (Source: Significant Developments)

Tanabe Research Says U.S. FDA Accepted Its IND Application For TR1801-ADC
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>::TANABE RESEARCH LABORATORIES U.S.A. SAYS FDA ACCEPTED ITS IND APPLICATION FOR TR1801-ADC (MT-8633), AN ADC TARGETING CMET POSITIVE SOLID TUMORS.  Full Article

AstraZeneca Q4 Core EPS $1.58
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - AstraZeneca PLC ::FY REVENUE FELL 2 PERCENT TO 22.09 BILLION USD.QTRLY REPORTED EARNINGS PER SHARE $0.82.QTRLY CORE EARNINGS PER SHARE $1.58.BOARD HAS REAFFIRMED ITS COMMITMENT TO PROGRESSIVE DIVIDEND POLICY.QTRLY TOTAL REVENUE $6,417 MILLION VERSUS $5,777 MILLION REPORTED LAST YEAR.FULL-YEAR DIVIDEND PER SHARE $2.80.SEES FY 2019 CORE EARNINGS PER SHARE $3.50 TO $3.70."OUR NEW MEDICINES PERFORMED PARTICULARLY WELL ACROSS THERAPY AREAS AND EMERGING MARKETS BUSINESS WENT FROM STRENGTH TO STRENGTH".CORE OPERATING PROFIT IS ANTICIPATED TO GROW AT A FASTER RATE THAN PRODUCT SALES IN 2019.CORE EPS IS ANTICIPATED TO BE IMPACTED BY A HIGHER CORE TAX RATE IN FY 2019.2019 WILL BE A YEAR OF FOCUS ON CONTINUED PIPELINE DELIVERY.SEES FY CAPITAL EXPENDITURE IS EXPECTED TO BE BROADLY STABLE AND RESTRUCTURING EXPENSES ARE TARGETED TO REDUCE VERSUS. PRIOR YEAR.FY 19 CORE OPERATING PROFIT IS ANTICIPATED TO INCREASE, AHEAD OF PRODUCT SALES, BY A MID-TEENS PERCENTAGE VERSUS. FY 2018.FY 19 CORE OPERATING EXPENSES ARE EXPECTED TO INCREASE BY A LOW SINGLE-DIGIT PERCENTAGE.STRATEGY AND PLANS REMAIN UNCHANGED, WITH SALES GROWTH AND A FOCUS ON COST MANAGEMENT ANTICIPATED TO DRIVE GROWING OPERATING PROFIT.EXPECTS TO INCUR $0.4BN OF ONE-TIME RESTRUCTURING CHARGES, THE MAJORITY OF WHICH WOULD BE NON-CASH EXPENSES.IF FOREX RATES FOR FEB-DEC ARE AT AVERAGE OF RATES SEEN IN JAN, EXPECT A LOW SINGLE-DIGIT PERCENT ADVERSE IMPACT ON FY PRODUCT SALES, CORE EPS.  Full Article

Astrazeneca Says Forxiga Receives Positive EU CHMP Opinion
Friday, 1 Feb 2019 

Feb 1 (Reuters) - AstraZeneca PLC ::FORXIGA RECEIVES POSITIVE EU CHMP OPINION.FORXIGA RECEIVES POSITIVE EU CHMP OPINION.CHMP RECOMMENDED A NEW INDICATION FOR MARKETING AUTHORISATION OF FORXIGA (DAPAGLIFLOZIN).  Full Article

AstraZeneca Appoints José Baselga To Head R&D For Oncology
Monday, 7 Jan 2019 

Jan 7 (Reuters) - AstraZeneca PLC ::ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES.JOSÉ BASELGA, MD, PHD, APPOINTED TO HEAD RESEARCH AND DEVELOPMENT FOR ONCOLOGY (ADDS DROPPED WORD 'ONCOLOGY').RESEARCH AND DEVELOPMENT UNITS AND COMMERCIAL UNITS WILL EACH BE REPRESENTED ON SENIOR EXECUTIVE TEAM OF ASTRAZENECA.TO CREATE THERAPY AREA-FOCUSED RESEARCH AND DEVELOPMENT UNITS FOR DISCOVERY THROUGH TO LATE-STAGE DEVELOPMENT FOR BIOPHARMACEUTICALS & ONCOLOGY.TO ALSO CREATE MIRRORED COMMERCIAL UNITS - ONE FOR BIOPHARMACEUTICALS AND ONE FOR ONCOLOGY.  Full Article

Astrazeneca Says Lynparza Met Primary Endpoint In Solo-3 Trial
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL.ASTRAZENECA PLC - LYNPARZA MEETS PRIMARY ENDPOINT IN PHASE III SOLO-3 TRIAL FOR TREATMENT OF RELAPSED BRCA-MUTATED ADVANCED OVARIAN CANCER.ASTRAZENECA PLC - ASTRAZENECA AND MSD NOW PLAN TO DISCUSS RESULTS WITH FDA.  Full Article

Astrazeneca Says Phase III Rockies And Olympus Roxadustat Trials Met Primary Endpoints
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS.ASTRAZENECA PLC - PHASE III OLYMPUS AND ROCKIES TRIALS FOR ROXADUSTAT MET THEIR PRIMARY ENDPOINTS IN CHRONIC KIDNEY DISEASE PATIENTS WITH ANAEMIA.ASTRAZENECA PLC - PHASE III OLYMPUS AND ROCKIES TRIALS FOR ROXADUSTAT MET THEIR PRIMARY ENDPOINTS IN CHRONIC KIDNEY DISEASE PATIENTS WITH ANAEMIA.ASTRAZENECA PLC - OLYMPUS DEMONSTRATED A STATISTICALLY-SIGNIFICANT AND CLINICALLY-MEANINGFUL IMPROVEMENT IN HAEMOGLOBIN VERSUS. PLACEBO IN NON-DIALYSIS-DEPENDENT PATIENTS.ASTRAZENECA PLC - ROCKIES DEMONSTRATED A STATISTICALLY-SIGNIFICANT IMPROVEMENT IN HAEMOGLOBIN VERSUS. EPOETIN ALFA IN DIALYSIS-DEPENDENT PATIENTS.  Full Article

Astrazeneca Appoints Tony Mok As A Non-Executive Director
Friday, 14 Dec 2018 

Dec 14 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - WITH EFFECT FROM 1 JANUARY 2019, TONY MOK IS APPOINTED AS A NON-EXECUTIVE DIRECTOR.  Full Article

Aveo Oncology Collaborates With Astrazeneca
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Aveo Pharmaceuticals Inc ::AVEO ONCOLOGY ANNOUNCES IMMUNO-ONCOLOGY CLINICAL COLLABORATION WITH ASTRAZENECA.AVEO PHARMACEUTICALS INC - PHASE 1/2 STUDY WILL EVALUATE COMBINATION OF IMFINZI (DURVALUMAB) AND FOTIVDA (TIVOZANIB) IN FIRST-LINE HCC.AVEO PHARMACEUTICALS INC - AVEO WILL SERVE AS STUDY SPONSOR, WITH STUDY COSTS SHARED EQUALLY BY BOTH PARTIES.AVEO PHARMACEUTICALS INC - CLINICAL DRUG WILL BE SUPPLIED BY EACH RESPECTIVE COMPANY.AVEO PHARMACEUTICALS INC - PHASE 1 PORTION OF STUDY IS EXPECTED TO COMMENCE IN 2019..  Full Article

Astrazeneca Says Divestment Of Rights To Covis Completed
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - AstraZeneca PLC ::DIVESTMENT OF RIGHTS TO COVIS COMPLETED.  Full Article

Dynavax Technologies-AstraZeneca Informed Co Initial High-Level Results From Phase 2A Study Indicate Azd1419 Treatment Did Not Meet Primary Endpoint
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Dynavax Technologies Corp ::DYNAVAX TECHNOLOGIES - ASTRAZENECA INFORMED CO INITIAL HIGH-LEVEL RESULTS FROM PHASE 2A STUDY INDICATE AZD1419 TREATMENT DID NOT MEET PRIMARY ENDPOINT.DYNAVAX TECHNOLOGIES CORP - ASTRAZENECA WILL NOW REVIEW FULL DATA BEFORE DECIDING ON NEXT STEPS FOR AZD1419 PROGRAM.DYNAVAX TECHNOLOGIES SAYS AZD1419 TREATMENT APPEARED TO BE SAFE & WELL TOLERATED & STUDY CONFIRMED ACTIVATION OF TLR9 PATHWAY - SEC FILING.  Full Article

UPDATE 2-HSBC, stronger pound pressure FTSE 100; Greggs outshines mid-caps

* Indivior slips on U.S. Supreme Court ruling (Adds news items, updates to closing prices)